Organ-Specific Dosimetry Following Radiopharmaceutical Therapy for Metastatic Prostate Cancer

Authors

Frank J. Arturi, SUNY Downstate Health Sciences UniversityFollow
Nilanjan Haldar, Thomas Jefferson UniversityFollow
Shray Jain, Thomas Jefferson UniversityFollow
Gia Nguyen, Thomas Jefferson UniversityFollow
Jessie Dinome, Thomas Jefferson UniversityFollow
Firas Mourtada, Thomas Jefferson UniversityFollow
Lydia J. Wilson, PhD, Thomas Jefferson UniversityFollow

Files

Description

Introduction

• Radiopharmaceutical Therapy (RPT) uses radioactive agents to target cancer at the cellular level
• Lu-177 targeting prostate-specific membrane antigen (PSMA), known as 177Lu- PSMA-617, can be used to treat metastatic, castration-resistant prostate cancer (mCRPC)
• 177Lu-PSMA-617 treatments use a standard dose and treatment regimen for all patients
• Patients exhibit different side effects and tumor response during treatment

Publication Date

8-30-2024

Keywords

RPT, MIM, Lu-177, Dosimetry, PSMA, mCRPC, SPECT/CT, AI algorithm

Disciplines

Medicine and Health Sciences | Oncology | Radiation Medicine

Comments

Presented at the 2024 Jefferson Radiation Oncology Research Symposium.

Recommended Citation

Arturi, Frank J.; Haldar, Nilanjan; Jain, Shray; Nguyen, Gia; Dinome, Jessie; Mourtada, Firas; and Wilson, PhD, Lydia J., "Organ-Specific Dosimetry Following Radiopharmaceutical Therapy for Metastatic Prostate Cancer" (2024). Department of Radiation Oncology Posters. 3.
https://jdc.jefferson.edu/radoncposters/3